March 10, 2021 07:00 AM ESTUpdated March 12, 01:32 PM
R&D
Coronavirus

Eli Lil­ly tops up pos­i­tive PhI­II da­ta for its Covid-19 an­ti­body com­bo at ‘the op­ti­mal dose’

John Carroll

Editor & Founder

Eli Lil­ly has added an­oth­er brick in the wall of pos­i­tive da­ta as­sem­bled for its com­bo an­ti­body ther­a­py for Covid-19.

Its BLAZE-1 Phase III study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ali­gos’ tri­al for oral MASH treat­ment suc­ceeds, but place­bo group shows odd trend

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

Lasker Award goes to three sci­en­tists who pi­o­neered re­search be­hind GLP-1 drugs

Ex­clu­sive: Flag­ship-backed Va­lo Health los­es in­ter­im CEO ahead of key Phase 2 read­out

Stem cell start­up spun out of George Church’s lab rais­es $75M

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times